ATXN2 and spinocerebellar ataxia type 2: In SCA2, the disease protein ATXN2 could also represent a potential prognostic and/or therapeutic biomarker, as the amount of polyQ-expanded ATXN2 in, e.g., blood or CSF, may reflect the course of the disease and potential therapeutic success.